This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RUNX1 · Western blot design guide
RUNX1 Western Blot Planning Guide
Plan a RUNX1 Western blot around the catalog-observed 48.7 kDa band, image-backed PB9157 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
RUNX1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 48.7 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Skin | |
| Negative control | Oral mucosa |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 48.7 kDa |
| ⓘ | Localization | Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated RUNX1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Nasopharynx |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9157 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected RUNX1 Western Blot Band Size?
Use the product-observed 48.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 48.7 kDa | Matches the authoritative product WB observation. |
| 48.7 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected RUNX1 appearancePlan around 48.7 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 48.7 kDa; use this as the primary experimental expectation. |
| Calculated mass | 48.7 kDa from UniProt Q01196; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9157. |
| Situation | Likely cause | Next action |
|---|---|---|
| 48.7 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing RUNX1 band
PB9157 · RUNX1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for RUNX1 Western blot
🧪Use Skin as the first positive-control candidate and Oral mucosa as the HPA Not detected negative candidate.
Positive control: Skin (High)
Negative control: Oral mucosa (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for RUNX1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skin | Reported tissue cells | High | Protein (HPA) | HPA → |
| Nasopharynx | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced RUNX1 Western Blot Tips
Deeper troubleshooting and optimisation questions for RUNX1, answered from its protein features.
Which band should guide the blot?
Use 48.7 kDa, the observation attached to the authoritative PB9157 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 48.7 kDa expectation.
Which positive control should I start with?
Start with Skin, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Oral mucosa as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for RUNX1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9157 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
RUNX1 Western Blot Reagents
Human/Mouse/Rat-reactive RUNX1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-RUNX1/AML1 Antibody Picoband®
Cat # PB9157
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q01196
- Human Protein Atlas — RUNX1
- PB9157 product record
- PMC6013935 — Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ (EBioMedicine, 2018)
- PMC5648507 — Unique N-terminal sequences in two Runx1 isoforms are dispensable for Runx1 function (BMC developmental biology, 2017)
- PMC6669147 — RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells via KLF4-mediated transactivation of P57 (Haematologica, 2019)